The lancet oncology
-
The lancet oncology · Aug 2010
Comparative StudyBody-mass index and cancer mortality in the Asia-Pacific Cohort Studies Collaboration: pooled analyses of 424,519 participants.
Excess bodyweight is an established risk factor for several types of cancer, but there are sparse data from Asian populations, where the proportion of overweight and obese individuals is increasing rapidly and adiposity can be substantially greater for the same body-mass index (BMI) compared with people from Western populations. ⋯ National Health and Medical Research Council of Australia, Health Research Council of New Zealand, and Pfizer Inc.
-
The lancet oncology · Aug 2010
Multicenter StudySafety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study.
Results of two phase 3 trials have shown first-line bevacizumab in combination with chemotherapy improves clinical outcomes in patients with advanced or recurrent non-squamous non-small-cell lung cancer (NSCLC). The SAiL (MO19390) study was undertaken to assess the safety and efficacy of first-line bevacizumab combined with standard chemotherapy regimens in clinical practice. ⋯ F Hoffmann-La Roche Ltd.
-
The lancet oncology · Aug 2010
Comment Letter Meta AnalysisGPC5 rs2352028 variant and risk of lung cancer in never smokers.